Kyle R. Brimacombe

5.9k citations

46 papers · 1.8k indexed · 1 hit paper · h-index 20

Co-authors: Matthew D. Hall Min Shen Anton Simeonov Samarjit Patnaik Richard T. Eastman Jacob S. Roth Michael M. Gottesman Matthew B. Boxer
Topics: Drug Transport and Resistance Mechanisms (7 papers)Cancer, Hypoxia, and Metabolism (6 papers)Amino Acid Enzymes and Metabolism (4 papers)
Cited by: Infectious Diseases Oncology Cancer Research
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry NeuroImage
Partner nations: United States Sweden Canada

In The Last Decade

Kyle R. Brimacombe

44 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

2020 654 citations Richard T. Eastman, Jacob S. Roth et al. ACS Central Science profile →

Peers

Countries citing papers authored by Kyle R. Brimacombe

Since Specialization

Citations

This map shows the geographic impact of Kyle R. Brimacombe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle R. Brimacombe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle R. Brimacombe more than expected).

Fields of papers citing papers by Kyle R. Brimacombe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle R. Brimacombe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle R. Brimacombe. The network helps show where Kyle R. Brimacombe may publish in the future.

Co-authorship network of co-authors of Kyle R. Brimacombe

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle R. Brimacombe. A scholar is included among the top collaborators of Kyle R. Brimacombe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle R. Brimacombe. Kyle R. Brimacombe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A deep learning approach predicting the activity of COVID-19 therapeutics and vaccines against emerging variants 2024 ·npj Systems Biology and Applications ·(unknown),Işın Y. Comba,Eli Silvert,Michiel J.M. Niesen,(unknown),(unknown),(unknown),(unknown),(unknown),Kanny K. Wan,Kyle R. Brimacombe,AJ Venkatakrishnan,Venky Soundararajan	0
2	The NCATS Assay Guidance Manual programme: advancing the practice and rigour of preclinical translation 2022 ·Nature Reviews Drug Discovery ·Sarine Markossian,Kyle R. Brimacombe,G. Sitta Sittampalam,A Grossman,Nathan P. Coussens,James Inglese,Douglas S. Auld,William W. Chin,Christopher P. Austin,Matthew D. Hall	2
3	Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments 2021 ·Briefings in Bioinformatics ·Ziaurrehman Tanoli,Jehad Aldahdooh,(unknown),Yinyin Wang,(unknown),Maddalena Fratelli,(unknown),Marián Hajdúch,Florence Biétrix,Philip Gribbon,Andrea Zaliani,Matthew D. Hall,Min Shen,Kyle R. Brimacombe,Evgeny Kulesskiy,Jani Saarela,Krister Wennerberg,Markus Vähä‐Koskela,Jing Tang	8
4	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors 2020 ·Proceedings of the National Academy of Sciences ·(unknown),Adam Yasgar,T Teramoto,Myoung‐Hwa Lee,Dorjbal Dorjsuren,Richard T. Eastman,Nasir Malik,Alexey Zakharov,Wenxue Li,Muzna Bachani,Kyle R. Brimacombe,Joseph Steiner,Matthew D. Hall,Anuradha Balasubramanian,Ajit Jadhav,Radhakrishnan Padmanabhan,Anton Simeonov,Avindra Nath	33
5	Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19 2020 ·ACS Central Science ·Richard T. Eastman,Jacob S. Roth,Kyle R. Brimacombe,Anton Simeonov,Min Shen,Samarjit Patnaik,Matthew D. Hall	26
6	Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19breakdown → 2020 ·ACS Central Science ·Richard T. Eastman,Jacob S. Roth,Kyle R. Brimacombe,Anton Simeonov,Min Shen,Samarjit Patnaik,Matthew D. Hall	654
7	Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis 2019 ·Molecular Cancer Therapeutics ·Hilary A. Kenny,Madhu Lal‐Nag,Min Shen,(unknown),Dominik A. Nahotko,Kristen Wroblewski,Sarah Fazal,Siquan Chen,Chun-Yi Chiang,Yen‐Ju Chen,Kyle R. Brimacombe,Juan Marugán,Marc Ferrer,Ernst Lengyel	22
8	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein 2019 ·Molecular Pharmacology ·Tobie D. Lee,Olivia W. Lee,Kyle R. Brimacombe,Lu Chen,Rajarshi Guha,Sabrina Lusvarghi,(unknown),Carleen Klumpp‐Thomas,Robert W. Robey,Suresh V. Ambudkar,Min Shen,Michael M. Gottesman,Matthew D. Hall	22
9	Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors 2018 ·Bioorganic & Medicinal Chemistry ·Jason M. Rohde,Kyle R. Brimacombe,Li Liu,Michael E. Pacold,Adam Yasgar,Dorian M. Cheff,Tobie D. Lee,Ganesha Rai,Bolormaa Baljinnyam,Zhuyin Li,Anton Simeonov,Matthew D. Hall,Min Shen,David M. Sabatini,Matthew B. Boxer	35
10	High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2 2018 ·Journal of Biological Chemistry ·Nathan P. Coussens,Stephen C. Kales,Mark J. Henderson,Olivia W. Lee,Kurumi Y. Horiuchi,Yuren Wang,Qing Chen,Ekaterina Kuznetsova,Jianghong Wu,Sirisha Chakka,Dorian M. Cheff,Ken Cheng,Paul Shinn,Kyle R. Brimacombe,Min Shen,Anton Simeonov,Madhu Lal‐Nag,Haiching Ma,Ajit Jadhav,Matthew D. Hall	55
11	Exploring Drug Dosing Regimens In Vitro Using Real-Time 3D Spheroid Tumor Growth Assays 2017 ·SLAS DISCOVERY ·Madhu Lal‐Nag,Lauren McGee,Steven A. Titus,Kyle R. Brimacombe,Sam Michael,G. Sitta Sittampalam,Marc Ferrer	10
12	A high-content imaging-based screening pipeline for the systematic identification of anti-progeroid compounds 2015 ·Methods ·Nard Kubben,Kyle R. Brimacombe,(unknown),Zhuyin Li,Tom Misteli	46
13	Structure activity relationships of human galactokinase inhibitors 2014 ·Bioorganic & Medicinal Chemistry Letters ·Li Liu,Manshu Tang,Martin J. Walsh,Kyle R. Brimacombe,Rajan Pragani,Cordelle Tanega,Jason M. Rohde,Heather L. Baker,Elizabeth Fernández,(unknown),(unknown),William Leister,Douglas S. Auld,Min Shen,Kent Lai,Matthew B. Boxer	18
14	Structure–activity relationship studies and biological characterization of human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Damien Duveau,Adam Yasgar,Yuhong Wang,Xin Hu,Jennifer Kouznetsova,Kyle R. Brimacombe,Ajit Jadhav,Anton Simeonov,Craig J. Thomas,David J. Maloney	13
15	Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET 2011 ·Proceedings of the National Academy of Sciences ·Pavitra Kannan,Kyle R. Brimacombe,William Charles Kreisl,Jeih‐San Liow,Sami S. Zoghbi,Sanjay Telu,Yi Zhang,Victor W. Pike,Christer Halldin,Michael M. Gottesman,Robert B. Innis,Matthew D. Hall	45
16	N-desmethyl-Loperamide Is Selective for P-Glycoprotein among Three ATP-Binding Cassette Transporters at the Blood-Brain Barrier 2010 ·Drug Metabolism and Disposition ·Pavitra Kannan,Kyle R. Brimacombe,Sami S. Zoghbi,Jeih‐San Liow,Cheryl L. Morse,Andrew Taku,Victor W. Pike,Christer Halldin,Robert B. Innis,Michael M. Gottesman,Matthew D. Hall	38
17	A Dual-Fluorescence High-Throughput Cell Line System for Probing Multidrug Resistance 2009 ·Assay and Drug Development Technologies ·Kyle R. Brimacombe,Matthew D. Hall,Douglas S. Auld,James Inglese,Christopher P. Austin,Michael M. Gottesman,(unknown)	46
18	Muscleblind‐like 1 is a negative regulator of TGF‐β‐dependent epithelial–mesenchymal transition of atrioventricular canal endocardial cells 2009 ·Developmental Dynamics ·(unknown),Kyle R. Brimacombe,(unknown),Andrea N. Ladd	18
19	Cloning and embryonic expression patterns of the chicken CELF family 2007 ·Developmental Dynamics ·Kyle R. Brimacombe,Andrea N. Ladd	25
20	Development and Applications of the Bioassay Ontology (BAO) to Describe and Categorize High-Throughput Assays -- Assay Guidance Manual 2004 ·(unknown),(unknown),Kyle R. Brimacombe,Arthur Grossman,(unknown),(unknown),Christine Austin,B Bejcek,Marcie A. Glicksman,James Inglese,(unknown),Li Z,John P. McGee,Owen B. McManus,L. B. Minor,Andrew D. Napper,(unknown),Terry Riss,(unknown),Jeffrey R. Weidner	3

About Kyle R. Brimacombe

Kyle R. Brimacombe is a scholar working on Biophysics, Biochemistry and Oncology, having authored 46 papers that have together received 1.8k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (7 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Amino Acid Enzymes and Metabolism (4 papers). The work is most often cited by research in Infectious Diseases (517 citations), Oncology (302 citations) and Cancer Research (165 citations). Kyle R. Brimacombe has collaborated with scholars based in United States, Sweden and Canada. Frequent co-authors include Matthew D. Hall, Min Shen, Anton Simeonov, Samarjit Patnaik, Richard T. Eastman, Jacob S. Roth, Michael M. Gottesman, Matthew B. Boxer, Andrea N. Ladd and Gary L. Griffiths. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and NeuroImage.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact